CORCINCH-FMR
Heart Failure with Functional Mitral Regurgitation
Not SpecifiedActive
Key Facts
Indication
Heart Failure with Functional Mitral Regurgitation
Phase
Not Specified
Status
Active
Company
About Ancora Heart
Ancora Heart is a private, clinical-stage medical device company pioneering a novel, minimally invasive approach to treating heart failure. Its lead product, the AccuCinch Ventricular Restoration System, is the first percutaneous device designed to directly remodel the dilated left ventricle, targeting the underlying structural pathology of HFrEF. The company is currently advancing the technology through the pivotal CORCINCH-HF study, a global randomized controlled trial. With FDA Breakthrough Device Designation, Ancora Heart is positioned to address a significant unmet need in a large, chronic patient population with high morbidity and mortality.
View full company profile